Kolexia
Delabesse Eric Pharmacien
Delabesse Eric
Pharmacien
Oncopole Toulouse
Toulouse, France
205 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Leucémie-lymphome lymphoblastique à précurseurs B et T Maladie résiduelle Translocation génétique Leucémie-lymphome lymphoblastique à précurseurs B Tumeurs hématologiques Leucémie lymphoïde

Collaborateurs

Voir plus
Recher Christian
Recher Christian
Hôpital Purpan, Toulouse, France
Bertoli Sarah
Bertoli Sarah
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Huguet Francoise
Huguet Francoise
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Luquet Isabelle
Luquet Isabelle
Oncopole Toulouse, Toulouse, France

Industries

Voir plus
KEPHREN
1 collaboration(s)
Dernière en 2020
Amgen
1 collaboration(s)
Dernière en 2020
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Cancer medicine   26 février 2024
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Leukemia research   09 janvier 2024
IL-4Rα Inhibition for Severe "Eosinophilic Gastroenteritis, Allergy, and Anaphylaxis" Syndrome due to a Gain-of-Function Variant in STAT6.
Journal of clinical immunology   22 décembre 2023
HOMOZYGOUS CBL MUTATION IN B LYMPHOCYTES AFTER CBL-DRIVEN JMML IMPAIRS B CELL MATURATION, FUNCTION AND ANTIBACTERIAL IMMUNITY
10th International Symposium of the European Working Group on Myelodysplastic Syndrome (EWOG-MDS) and Severe Aplastic Anemia (SAA) in Childhood   01 décembre 2023
Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia.
Blood advances   21 novembre 2023
Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL.
The Journal of experimental medicine   06 novembre 2023
Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
65th ASH Annual Meeting Abstracts   02 novembre 2023
Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1-Mutated Acute Myeloid Leukemia - a Filo Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023